Literature DB >> 10194063

Rupture of the intestinal epithelial barrier and mucosal invasion by Shigella flexneri.

P J Sansonetti1, G Tran Van Nhieu, C Egile.   

Abstract

Invasion of the intestinal barrier by Shigella flexneri involves complex interactions with epithelial and phagocytic cells. Major perturbation of the signals that maintain epithelial integrity permits mucosal invasion, leading to tissue destruction. Expression of this invasive phenotype depends on the secretion of Ipa proteins (invasins), which can trigger entry of the pathogen into epithelial cells by causing massive rearrangement of the host cell cytoskeleton and cause macrophage apoptotic death by direct interaction of IpaB with interleukin-1beta (IL-1beta)-converting enzyme. This results in the killing of defense cells and in the release of IL-1beta. In vivo, bacteria translocate through the epithelial barrier, essentially via M cells of the follicle-associated epithelium in the colonic and rectal mucosa. Apoptotic death of macrophages in subepithelial tissues allows bacterial survival and triggers inflammation, which destabilizes epithelial structures and facilitates further bacterial entry. Once they are intracellular, bacteria multiply within the cytoplasm and move from cell to cell by an actin-dependent process.

Entities:  

Mesh:

Year:  1999        PMID: 10194063     DOI: 10.1086/515150

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  26 in total

Review 1.  Breaching the mucosal barrier by stealth: an emerging pathogenic mechanism for enteroadherent bacterial pathogens.

Authors:  J M Fleckenstein; D J Kopecko
Journal:  J Clin Invest       Date:  2001-01       Impact factor: 14.808

2.  Spa33, a cell surface-associated subunit of the Mxi-Spa type III secretory pathway of Shigella flexneri, regulates Ipa protein traffic.

Authors:  R Schuch; A T Maurelli
Journal:  Infect Immun       Date:  2001-04       Impact factor: 3.441

Review 3.  Mechanisms of bacterial pathogenicity.

Authors:  J W Wilson; M J Schurr; C L LeBlanc; R Ramamurthy; K L Buchanan; C A Nickerson
Journal:  Postgrad Med J       Date:  2002-04       Impact factor: 2.401

Review 4.  Use of aminoglycosides in treatment of infections due to intracellular bacteria.

Authors:  M Maurin; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

5.  Vibrio cholerae-induced inflammation in the neonatal mouse cholera model.

Authors:  Anne L Bishop; Bharathi Patimalla; Andrew Camilli
Journal:  Infect Immun       Date:  2014-03-31       Impact factor: 3.441

Review 6.  The pathogenesis of Shigella flexneri infection: lessons from in vitro and in vivo studies.

Authors:  D J Philpott; J D Edgeworth; P J Sansonetti
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

Review 7.  Questions about the behaviour of bacterial pathogens in vivo.

Authors:  H Smith
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2000-05-29       Impact factor: 6.237

8.  The iron-responsive Fur/RyhB regulatory cascade modulates the Shigella outer membrane protease IcsP.

Authors:  Lia A A Africa; Erin R Murphy; Nicholas R Egan; Amanda F Wigley; Helen J Wing
Journal:  Infect Immun       Date:  2011-08-22       Impact factor: 3.441

9.  Sumoylation controls host anti-bacterial response to the gut invasive pathogen Shigella flexneri.

Authors:  Sabrina Fritah; Nouara Lhocine; Filip Golebiowski; Joëlle Mounier; Alexandra Andrieux; Grégory Jouvion; Ronald T Hay; Philippe Sansonetti; Anne Dejean
Journal:  EMBO Rep       Date:  2014-08-05       Impact factor: 8.807

10.  Detection of Shigella by a PCR assay targeting the ipaH gene suggests increased prevalence of shigellosis in Nha Trang, Vietnam.

Authors:  Dinh Thiem Vu; Orntipa Sethabutr; Lorenz Von Seidlein; Van Tung Tran; Gia Canh Do; Trong Chien Bui; Huu Tho Le; Hyejon Lee; Huo-Shu Houng; Thomas L Hale; John D Clemens; Carl Mason; Duc Trach Dang
Journal:  J Clin Microbiol       Date:  2004-05       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.